AAN: Tavapadon as Adjunct to Levodopa Ups Daily ON Time in Parkinson Disease
By Elana Gotkine HealthDay Reporter
TUESDAY, April 8, 2025 -- For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time versus placebo, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 5 to 9 in San Diego.
Hubert Fernandez, M.D., from the Cleveland Clinic, and colleagues conducted a phase 3, placebo-controlled, double-blind trial to examine adjunctive therapy with tavapadon in adults experiencing motor fluctuations while receiving stable levodopa treatment. A total of 507 patients (aged 40 to 80 years) were enrolled and randomly assigned to adjunctive tavapadon (titrated to maximum tolerated flexible dose: 5 to 15 mg daily) or placebo in a 1:1 ratio.
The researchers found that tavapadon treatment significantly increased total daily ON time without troublesome dyskinesia (1.7 hours versus 0.6 hours with placebo). There was also a significant reduction in the change from baseline in daily OFF time compared with placebo. The safety profile of tavapadon was consistent with that seen in previous clinical trials; most adverse events were mild to moderate in severity.
"These findings in adults with Parkinson's disease and motor fluctuations demonstrate the efficacy and acceptable safety profile of tavapadon as adjunctive therapy to levodopa," the authors write.
The study was funded by AbbVie, the manufacturer of tavapadon.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Common Medications Tied to Older Age at Onset of Parkinson Disease
FRIDAY, April 25, 2025 -- Multiple common medications are associated with a considerable delay of Parkinson disease (PD) symptom onset, according to a study published online March...
Globally, 25.2 Million Projected to Be Living With Parkinson Disease in 2050
MONDAY, March 10, 2025 -- The prevalence of Parkinson disease is projected to increase through 2050, according to a study published online March 5 in The BMJ. Using data from the...
AAN: Obstructive Sleep Apnea Linked to Increased Incidence of Parkinson Disease
TUESDAY, March 4, 2025 -- Obstructive sleep apnea (OSA) is associated with an increased risk for Parkinson disease (PD), according to a study scheduled for presentation at the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.